Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bladder urothelial surface refers to the apical membrane of the bladder’s urothelium, a stratified epithelial tissue lining the interior of the urinary bladder. This surface is dominated by specialized cells called umbrella cells, whose apical facets are covered with dense plaques formed by uroplakin protein complexes (UPIa, UPIb, UPII, UPIIIa). The urothelial surface creates a physical and molecular barrier that restricts the passage of water, solutes, toxins, and pathogens from urine into underlying tissues and systemic circulation. It is highly adaptive, expanding and contracting with bladder filling, and can rapidly replace damaged cells in response to injury or infection. While the surface itself is not a discrete therapeutic target, defects within its structure contribute to various bladder diseases, making the study of its configuration and constituent molecules (especially uroplakins) essential for understanding and addressing urothelial pathophysiology.
None directly for "surface"; for drugs acting on uroplakins or epithelium: may involve barrier reinforcement, anti-inflammatory effect, signaling modulation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bladder urothelium apical surface.